Issue: April 2019
April 08, 2019
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
PARTNER 3
Issue: April 2019
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Researchers assessed the efficacy and safety of a transcatheter heart valve (Sapien 3, Edwards Lifesciences) for the treatment of patients with severe aortic stenosis at low risk for surgery.